Compare Alphabet Inc Class A (GOOGL) vs Inovio Pharmaceuticals Inc (INO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alphabet Inc Class A vs Inovio Pharmaceuticals Inc — how do they compare? Alphabet Inc Class A trades at $355.4 (market cap $4.52T), while Inovio Pharmaceuticals Inc trades at $1.12 (market cap $96.26M). The key difference: Alphabet Inc Class A is far larger — about 46956.2× Inovio Pharmaceuticals Inc's market cap, and Alphabet Inc Class A pays a 0.24% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| GOOGL | INO | |
|---|---|---|
Market Cap | $4.52T | $96.26M |
Sector | Media | Health |
52-Week High | $402.62 | $2.87 |
52-Week Low | $182.97 | $1.05 |
Enterprise Value | $4.49T | $67.27M |
Dividend Yield | 0.24% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Alphabet (GOOGL) trades at $354.37, down 1.43% on the day, amid a bullish technical setup with strong analyst support. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $5.11 significantly exceeding the $2.64 estimate. Financial health is solid, with 2025 revenue of $402.84 billion and net income of $132.17 billion, reflecting a net margin of 32.8%. Positive news flow highlights AI-driven growth and strategic partnerships.
Outlook remains positive given earnings momentum, AI expansion, and a consensus price target of $431.78 implying 22% upside. Risks include antitrust scrutiny and tech sector volatility. Institutional sentiment is strongly bullish with 85% buy ratings, supporting a favorable risk-reward profile for long-term investors.
INO trades at $1.14, down 1.72% today, with a bearish technical signal from moving averages. The company shows minimal revenue of $65,340 in 2025 but has consistently beaten EPS estimates recently. Cash flow remains negative, though operating expenses are declining. A key FDA decision on INO-3107 is expected by October 30, 2026, representing a major catalyst.
The outlook hinges on regulatory approval for INO-3107. While analyst consensus is moderately bullish (53% buy ratings), significant financial losses and high valuation ratios pose substantial risks. The stock is a high-risk, event-driven investment dependent on successful drug commercialization to reverse its negative profitability trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alphabet Inc Class A
Alphabet, the parent company of Google, earns nearly 90% of its revenue from Google services, mainly through advertising. Other revenue comes from subscriptions (YouTube TV, YouTube Music), platform sales (Play Store purchases), and devices (Pixel, Chromebooks, Chromecast). Google Cloud contributes around 10%, while investments in self-driving cars (Waymo), health (Verily), and internet access (Google Fiber) make up the rest.
Read more on GOOGL →About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →
